BRCA1 and triple-negative breast carcinoma: In particular, subsets of certain cancers, such as triple-negative breast cancer (10–15%) [5] and castration-resistant prostate cancer (13.6%) [6], have a higher prevalence of BRCA1/2 mutations than does the whole population of that cancer.